VolutionRx报告财年业绩

2025-04-01 04:22

VolitionRX press release (NYSE:VNRX): FY Revenue of $1.2M, up 59% over the prior year, misses by $0.36M.
Nu.Q® Vet revenue up 75% and Nu.Q® Discover revenue up 40% versus 2023.
Operating expenses were down by 23% vs prior year as cost reduction measures took effect, with second half expenses down by 31%.
Cash and cash equivalents as of December 31, 2024, totaled approximately $3.3 million.
Subsequent to year-end received $1.8 million of non-dilutive funding from Belgian institutions, with more funding expected in 2025.
Subsequent to year-end raised approximately $2.3 million in a registered direct offering to investors.
Goal to be cash neutral in 2025, meaning income, including licensing receipts, matches expenditure on a cash basis.
Shares -1.77%.

More on VolitionRX